PepGen, Inc. (NASDAQ:PEPG) Given Average Rating of “Moderate Buy” by Analysts

Shares of PepGen, Inc. (NASDAQ:PEPG) have been given a consensus rating of “Moderate Buy” by the five brokerages that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $11.75.

PEPG has been the topic of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of PepGen in a research report on Thursday, January 22nd. Wall Street Zen upgraded shares of PepGen from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, HC Wainwright increased their price target on shares of PepGen from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th.

PepGen Stock Up 5.5%

PEPG opened at $5.60 on Wednesday. The business has a 50 day moving average of $5.77 and a 200-day moving average of $3.88. The stock has a market cap of $385 million, a PE ratio of -1.99 and a beta of 1.91. PepGen has a 52 week low of $0.88 and a 52 week high of $7.80.

PepGen (NASDAQ:PEPG) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.11. Equities analysts anticipate that PepGen will post -2.73 EPS for the current year.

Institutional Trading of PepGen

A number of hedge funds and other institutional investors have recently modified their holdings of PEPG. RA Capital Management L.P. boosted its stake in shares of PepGen by 87.7% in the third quarter. RA Capital Management L.P. now owns 20,064,545 shares of the company’s stock worth $92,698,000 after acquiring an additional 9,375,000 shares during the period. Commodore Capital LP bought a new position in PepGen in the 3rd quarter worth approximately $10,891,000. Vivo Capital LLC purchased a new stake in PepGen during the 3rd quarter valued at approximately $10,742,000. Viking Global Investors LP grew its holdings in PepGen by 134.9% during the 3rd quarter. Viking Global Investors LP now owns 3,482,434 shares of the company’s stock valued at $16,089,000 after buying an additional 2,000,000 shares in the last quarter. Finally, Deep Track Capital LP bought a new stake in shares of PepGen during the third quarter valued at approximately $5,544,000. 58.01% of the stock is owned by hedge funds and other institutional investors.

About PepGen

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).